Mobile App for MG Patients Being Developed by BrightInsight, UCB

Teresa Carvalho, MS avatar

by Teresa Carvalho, MS |

Share this article:

Share article via email
A woman shouts into a megaphone.

Software maker BrightInsight is teaming up with the biopharmaceutical company UCB to develop and commercialize a new mobile app to help people with myasthenia gravis (MG) manage their disease and improve their care and clinical outcomes.

“MG is a rare, challenging and unpredictable disease, and innovation is urgently needed to better support those living with it. This partnership takes us one step forward in our goal to harness digital solutions and the latest AI [artificial intelligence] technologies to better serve patients and potentially improve their care,” Colin Lake, vice president and head of digital business transformation neurology at UCB, said in a press release.

The new mobile app will be available first in the U.S. The companies expect to launch an optimized version for MG and other rare diseases worldwide, based on feedback from U.S. patients.

Recommended Reading
A woman shouts into a megaphone.

Redesigned Patient Website Launched by Janssen for Its US Campaign

“We are excited to partner with BrightInsight, strengthening our commitment to addressing unmet needs in the rare disease space, and putting patients at the forefront of our innovations,” Lake said.

The app will be the first installment of the larger digital disease management solution the two companies are working on to support rare disease patients. The digital disease management tool leverages BrightInsight Platform, a platform created on Google Cloud that seeks to advance the development of digital tools from several therapeutic areas, including apps, medical devices, and diagnostic tools, and bring them to market.

“We are pleased to be UCB’s digital health partner and to collaborate with them to bring digital solutions to patients with rare diseases. Our collaboration reflects our companies’ common goal to develop digital health solutions for disease management that enable better patient experiences and outcomes,” said Kal Patel, MD, CEO and co-founder of BrightInsight.

The platform was designed under a strict quality control that allows UCB to distribute its tool worldwide while complying with privacy, security, and regulatory requirements, the company reported.

“BrightInsight welcomes UCB to our growing list of innovative, global biopharma partners who are prioritizing digital health and who rely on our proven platform to bring compliant digital solutions to market,” Patel said.